Cybin Inc. Common Stock (HELP NASDAQ) stock market data APIs
$13.0781
0.2(1.5%)
as of September 11, 2026
Try our APIs with
free plan!
Cybin Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Prev. Close
13.0781
Open
13.2746
High
13.5133
Low
12.6112
52 wk Range
3.76-14.35
Market Cap
938 M
Shares Outstanding
73 060 K
EPS
-0.91
Beta
0.632
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cybin Inc. Common Stock data using free add-ons & libraries
Get Cybin Inc. Common Stock Fundamental Data
Cybin Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -166 936 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cybin Inc. Common Stock News
New
FDA names acting heads of drug and vaccine units to permanent roles
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House ad...
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Helus Pharma CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HEL...
Cybin reports Q1 results
* Cybin press release [https://seekingalpha.com/pr/20619592-helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business] (HELP [https://seekingalpha.com/symbol/HELP]): Q1 Ne...
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately. Halstead brings 25 years of industry experie...
Get Cybin Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
